Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist

Gareth Sheridan, CEO of Nutriband Inc., has been selected as a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards, marking a significant milestone for the life sciences company focused on transdermal drug delivery and abuse-deterrent technologies.

The prestigious awards program recognized Sheridan among 27 Irish entrepreneurs, representing 24 companies generating over €1 billion in annual revenue. His selection underscores the company's innovative approach to addressing critical challenges in pain management and pharmaceutical safety.

Nutriband's lead product, AVERSA™, represents a breakthrough in preventing opioid patch misuse and abuse. The technology can be incorporated into transdermal patches to mitigate potential drug diversion, accidental exposure, and improper usage—a significant advancement in pharmaceutical safety.

As a finalist, Sheridan will participate in a CEO retreat in Japan and compete for the overall Entrepreneur of the Year title, which will be awarded at a gala event in November. This recognition highlights not only Sheridan's leadership but also Nutriband's transformation from an early-stage startup to a U.S.-listed life sciences company.

The EY Entrepreneur of the Year Award serves as a critical platform for acknowledging innovative leaders who are driving meaningful change in their industries. For Nutriband, this recognition validates the company's commitment to developing cutting-edge pharmaceutical technologies that prioritize patient safety and address complex healthcare challenges.

By focusing on abuse-deterrent technologies, Nutriband is positioning itself at the forefront of addressing the ongoing opioid crisis, offering potential solutions that could significantly impact patient care and pharmaceutical safety strategies.